First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy
January 23, 2023 07:01 ET
|
Consilium Strategic Communications
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy Phase I/II trial will assess safety and efficacy of SMART101 in accelerating immune reconstitution to...
4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement
December 06, 2022 08:07 ET
|
Consilium Strategic Communications
Press Release 4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement Company’s proprietary end-to-end...
Patients will benefit if Europe modernizes its policy framework to reflect the distinct promise of cell and gene therapy, the Alliance for Regenerative Medicine will highlight in 29 November EU Parliament event
November 24, 2022 04:30 ET
|
Consilium Strategic Communications
Patients will benefit if Europe modernizes its policy framework to reflect the distinct promise of cell and gene therapy, the Alliance for Regenerative Medicine will highlight in 29 November EU...
Achilles Therapeutics to present at the 39th Annual J.P. Morgan Healthcare Conference
January 07, 2021 07:00 ET
|
Consilium Strategic Communications
Achilles Therapeutics to present at the 39th Annual J.P. Morgan Healthcare Conference London, UK 7 January 2021 – Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company...
Immunocore Appoints Nobel Laureate Professor Sir Peter J. Ratcliffe as Non-Executive Director
October 15, 2020 07:00 ET
|
Consilium Strategic Communications
PRESS RELEASE Immunocore Appoints Nobel Laureate Professor Sir Peter J. Ratcliffe as Non-Executive Director (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 15...
Immunocore Appoints Nobel Laureate Professor Sir Peter J. Ratcliffe as Non-Executive Director
October 15, 2020 02:00 ET
|
Consilium Strategic Communications
PRESS RELEASE Immunocore Appoints Nobel Laureate Professor Sir Peter J. Ratcliffe as Non-Executive Director (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 15...
Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America
September 02, 2019 08:30 ET
|
Consilium Strategic Communications
Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America Lugano, Switzerland, São Paulo, Brazil, and Buenos Aires,...
CMR Surgical raises $100 million in a Series B financing
June 04, 2018 02:00 ET
|
Consilium Strategic Communications
CMR Surgical Limited ("CMR Surgical" or the "Company") CMR Surgical raises $100 million in a Series B financing Europe’s largest medical device financing paves way to Versius® commercialisation ...
Helsinn announces EUR6 million investment in Helsinn Birex Pharmaceuticals to safeguard the quality and authenticity of its products
May 24, 2018 03:30 ET
|
Consilium Strategic Communications
Helsinn announces EUR6 million investment in Helsinn Birex Pharmaceuticals to safeguard the quality and authenticity of its products Lugano, Switzerland, May 24, 2018 – Helsinn, a Swiss...